{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:14:33Z","timestamp":1772820873742,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-026-00893-4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:37:42Z","timestamp":1770813462000},"page":"753-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04418765","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-8881","authenticated-orcid":false,"given":"Line Pickering","family":"Boserup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-7404","authenticated-orcid":false,"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1102-3756","authenticated-orcid":false,"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4927","authenticated-orcid":false,"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"10440","key":"893_CR1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","unstructured":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361.","journal-title":"Lancet."},{"issue":"4","key":"893_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1526-4610.2007.00993.x","volume":"48","author":"N Jette","year":"2008","unstructured":"Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders--a national population-based study. Headache. 2008;48(4):501\u201316.","journal-title":"Headache"},{"issue":"24","key":"893_CR3","doi-asserted-by":"publisher","first-page":"e2224","DOI":"10.1212\/WNL.0000000000008589","volume":"93","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Fanning KM, Buse DC, et al. Migraine progression in subgroups of migraine based on comorbidities: results of the CaMEO Study. Neurology. 2019;93(24):e2224\u201336.","journal-title":"Neurology"},{"issue":"12","key":"893_CR4","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","volume":"270","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Nahas SJ, et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023;270(12):5692\u2013710.","journal-title":"J Neurol"},{"issue":"6","key":"893_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/jamaneurol.2025.0806","volume":"82","author":"RB Lipton","year":"2025","unstructured":"Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, et al. Fremanezumab for the treatment of patients with migraine and comorbid major depressive disorder: the UNITE randomized clinical trial. JAMA Neurol. 2025;82(6):560\u20139.","journal-title":"JAMA Neurol"},{"issue":"13","key":"893_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134526","volume":"12","author":"M Vikelis","year":"2023","unstructured":"Vikelis M, Dermitzakis EV, Xiromerisiou G, et al. Effects of fremanezumab on psychiatric comorbidities in difficult-to-treat patients with chronic migraine: post hoc analysis of a prospective, multicenter, real-world Greek registry. J Clin Med. 2023;12(13):4526.","journal-title":"J Clin Med"},{"issue":"2","key":"893_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16106","volume":"31","author":"LS de Vries","year":"2024","unstructured":"de Vries LS, van der Arend BWH, de Boer I, et al. Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. Eur J Neurol. 2024;31(2):e16106.","journal-title":"Eur J Neurol"},{"issue":"3","key":"893_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40120-024-00591-z","volume":"13","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Egeo G, Proietti S, et al. Assessing the long-term (48-week) effectiveness, safety, and tolerability of fremanezumab in migraine in real life: insights from the multicenter, prospective, FRIEND3 study. Neurol Ther. 2024;13(3):611\u201324.","journal-title":"Neurol Ther"},{"key":"893_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041054","author":"M Polanco","year":"2025","unstructured":"Polanco M, Garate G, Sanchez-Gudin J, et al. Real-world lessons with fremanezumab as the third available CGRP monoclonal antibody in a third-level hospital: focus on the factors predicting response. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14041054.","journal-title":"J Clin Med"},{"issue":"4","key":"893_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Cohen JM, Galic M, et al. Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache. 2021;61(4):662\u201372.","journal-title":"Headache"},{"issue":"17 Suppl 1","key":"893_CR11","first-page":"P4","volume":"102","author":"C Argoff","year":"2024","unstructured":"Argoff C, Herzog S, Smith R, et al. Impact of psychiatric conditions on the real-world effectiveness of eptinezumab treatment in patients with chronic migraine. Neurology. 2024;102(17 Suppl 1):P4-12.005.","journal-title":"Neurology."},{"issue":"12","key":"893_CR12","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1007\/s10072-024-07769-1","volume":"45","author":"S Migliore","year":"2024","unstructured":"Migliore S, Altamura C, Brunelli N, et al. Psychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life. Neurol Sci. 2024;45(12):5813\u201321.","journal-title":"Neurol Sci"},{"issue":"1","key":"893_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01690-2","volume":"24","author":"V Obach","year":"2023","unstructured":"Obach V, Velasco F, Alvarez Escudero R, et al. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry. J Headache Pain. 2023;24(1):157.","journal-title":"J Headache Pain"},{"key":"893_CR14","unstructured":"VYEPTI\u00ae (eptinezumab-jjmr) injection, for intravenous use. Prescribing information. Lundbeck Seattle BioPharmaceuticals, Inc.; 2025. Accessed August 26, 2025. Available from: https:\/\/www.vyepti.com\/."},{"issue":"7","key":"893_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597\u2013607.","journal-title":"Lancet Neurol"},{"issue":"1","key":"893_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s10194-023-01688-w","volume":"24","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Gendolla A, et al. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. J Headache Pain. 2023;24(1):155.","journal-title":"J Headache Pain"},{"key":"893_CR17","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"9","key":"893_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102420919098","volume":"40","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Evers S. International classification of headache disorders\u2014ICHD-4 alpha. Cephalalgia. 2020;40(9):887\u20138.","journal-title":"Cephalalgia"},{"key":"893_CR19","unstructured":"DSM-5. Diagnostic and statistical manual of mental disorders (fifth edition): American Psychiatric Association; 2013."},{"issue":"5","key":"893_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815\u201332.","journal-title":"Cephalalgia"},{"issue":"1","key":"893_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-022-01418-8","volume":"23","author":"R Apelian","year":"2022","unstructured":"Apelian R, Boyle L, Hirman J, Asher D. Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2. J Headache Pain. 2022;23(1):48.","journal-title":"J Headache Pain"},{"issue":"1","key":"893_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01366-9","volume":"22","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain. 2021;22(1):151.","journal-title":"J Headache Pain"},{"issue":"2","key":"893_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231222923","volume":"44","author":"M Torres-Ferrus","year":"2024","unstructured":"Torres-Ferrus M, Gallardo VJ, Alpuente A, et al. Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies. Cephalalgia. 2024;44(2):3331024231222923.","journal-title":"Cephalalgia"},{"issue":"10","key":"893_CR24","first-page":"927","volume":"95","author":"E Caronna","year":"2024","unstructured":"Caronna E, Gallardo VJ, Egeo G, et al. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry. 2024;95(10):927\u201337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"893_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10194-010-0282-4","volume":"12","author":"F Antonaci","year":"2011","unstructured":"Antonaci F, Nappi G, Galli F, et al. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain. 2011;12(2):115\u201325.","journal-title":"J Headache Pain"},{"issue":"1","key":"893_CR26","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1038\/s41598-021-87352-2","volume":"11","author":"P Irimia","year":"2021","unstructured":"Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, et al. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas. Sci Rep. 2021;11(1):8286.","journal-title":"Sci Rep"},{"issue":"2","key":"893_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4103\/ipj.ipj_60_23","volume":"33","author":"P Sharma","year":"2024","unstructured":"Sharma P, Kumar S, Dixit V, Sharma CS, Chaudhury S. Psychiatric comorbidity in patients with migraine: a standardized interview-based study. Ind Psychiatry J. 2024;33(2):266\u201374.","journal-title":"Ind Psychiatry J"},{"issue":"9","key":"893_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.18203\/2349-3933.ijam20222098","volume":"9","author":"H Ismail","year":"2022","unstructured":"Ismail H, Fayaz F. Psychiatric comorbidity in patients with migraine. Int J Adv Med. 2022;9(9):924\u20137.","journal-title":"Int J Adv Med"},{"issue":"1","key":"893_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-34","volume":"14","author":"M Semiz","year":"2013","unstructured":"Semiz M, Senturk IA, Balaban H, Yagiz AK, Kavakci O. Prevalence of migraine and co-morbid psychiatric disorders among students of Cumhuriyet University. J Headache Pain. 2013;14(1):34.","journal-title":"J Headache Pain"},{"issue":"10","key":"893_CR30","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/head.13970","volume":"60","author":"TA Smitherman","year":"2020","unstructured":"Smitherman TA, Tietjen GE, Schuh K, et al. Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and\/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies. Headache. 2020;60(10):2202\u201319.","journal-title":"Headache"},{"issue":"1","key":"893_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0742-1","volume":"18","author":"MFP Peres","year":"2017","unstructured":"Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain. 2017;18(1):37.","journal-title":"J Headache Pain"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00893-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:07:58Z","timestamp":1772798878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00893-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00893-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patricia Pozo-Rosich, in the past 36\u00a0months, has received honoraria as a consultant and speaker from AbbVie, Almirall, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Otsuka Pharmaceuticals, Pfizer, and Teva. Her research group has received research grants from AbbVie, AGAUR, EraNet Neuron, FEDER RIS3CAT, Instituto Investigaci\u00f3n Carlos III, MICINN, Novartis, and Teva and funding for clinical trials from AbbVie, Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva. She is the Honorary Secretary of the International Headache Society, a member of the Clinical Trials Guidelines Committee of the International Headache Society, an associate editor for\n                      Cephalalgia\n                      and\n                      Neurologia\n                      , and the founder of\n                      \n                      , a platform to give information and tools to physicians and people who suffer from migraine and other headaches. Cristina Tassorelli, in the past 36\u00a0months, has been Principal Investigator in clinical trials sponsored by AbbVie, Biohaven, Eli Lilly, Ipsen, Lundbeck, Pfizer, and Teva and has received: support (financial or drugs) from AbbVie and Novartis for an investigator-initiated trial; consulting fees for the participation in advisory boards from AbbVie, Domp\u00e9, Eli Lilly, Ipsen, Lundbeck, Medscape, Pfizer, and Teva; honoraria for scientific lectures and presentations from AbbVie, Eli Lilly, Lundbeck, Pfizer, and Teva; support for attending meetings from AbbVie, Domp\u00e9, Eli Lilly, Ipsen, Lundbeck, Pfizer, and Teva; and grants from the European Commission, the Italian Ministry of Health, and the Italian Ministry of University. Line Pickering Boserup and Susanne F. Awad are full-time employees of H. Lundbeck A\/S. Xin Ying Lee was a full-time employee of H. Lundbeck A\/S during data analysis and initial manuscript stages. She is currently an employee of Novo Nordisk, which was not involved in nor has competing interest with this study. Jessica Ailani, in the past 36\u00a0months, has served as a consultant for AbbVie, Aeon, Dr. Reddy\u2019s, Eli Lilly, eNeura, GlaxoSmithKline, Gore, Ipsen, Linpharma, Lundbeck, Merz, Neurolief, Pfizer, Satsuma, Scilex, Theranica, Tonix, and Vectura Fertin; has received clinical trial support from AbbVie, Ipsen, Lundbeck, Mi-Helper, and Parema; and has provided editorial services to\n                      SELF\n                      magazine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted in compliance with current Good Clinical Practices as defined in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines, local regulatory requirements, and the Declaration of Helsinki policy statement. The local review board or a central institutional review board\/ethics committee approved all study documentation at each of the 96 study sites across Europe and the US (Table\n                      \n                      ). All participants provided written informed consent prior to trial participation. DELIVER is registered on ClinicalTrials. gov (NCT04418765) and EudraCT (2019\u2013004497\u201325).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}